On the cusp of change: New therapeutic modalities for HCV
We are at the cusp of significant new alternatives for the treatment of chronic hepatitis C. Among more than 100 drugs in development, some are ready to be approved and in the market as soon as next year. The protease inhibitors Telaprevir and Boceprevir, will change the SOC treatment to triple ther...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2010-01-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119317375 |
| _version_ | 1798032885881503744 |
|---|---|
| author | Maribel Rodríguez-Torres |
| author_facet | Maribel Rodríguez-Torres |
| author_sort | Maribel Rodríguez-Torres |
| collection | DOAJ |
| description | We are at the cusp of significant new alternatives for the treatment of chronic hepatitis C. Among more than 100 drugs in development, some are ready to be approved and in the market as soon as next year. The protease inhibitors Telaprevir and Boceprevir, will change the SOC treatment to triple therapy, (combined with peg IFN and RBV), with duration of treatment guided by rapid virological response. In this article we present the data supporting the approval of Telaprevir and Boceprevir, and information on polymerase inhibitors and IFN free proof of concept trials. Finally we discuss which patients should wait for DAA based therapies and which should be considered for peg IFN/RBV now.In the next 5 years our patients can expect higher response rates and truncated duration of therapy. They can expect drug cocktails or combos but for the next years these novel drugs will still require peg IFN and RBV. Also, a new era of resistance as a barrier to therapy will require sub typing and more viral monitoring. Overall, improved outcomes will come at the expense of more adverse events and increased costs of treatment. |
| first_indexed | 2024-04-11T20:21:07Z |
| format | Article |
| id | doaj.art-27b97084c8004fef99200b546e935b09 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-04-11T20:21:07Z |
| publishDate | 2010-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-27b97084c8004fef99200b546e935b092022-12-22T04:04:48ZengElsevierAnnals of Hepatology1665-26812010-01-019S123S131On the cusp of change: New therapeutic modalities for HCVMaribel Rodríguez-Torres0Fundación de Investigación de Diego, San Juan, Puerto Rico.; Correspondence and reprint request: Maribel Rodríguez-Torres, M.D., CPI Fundación de Investigación de Diego San Juan, Puerto Rico Avenida d3e Diego 359, San Juan, Puerto Rico 00909We are at the cusp of significant new alternatives for the treatment of chronic hepatitis C. Among more than 100 drugs in development, some are ready to be approved and in the market as soon as next year. The protease inhibitors Telaprevir and Boceprevir, will change the SOC treatment to triple therapy, (combined with peg IFN and RBV), with duration of treatment guided by rapid virological response. In this article we present the data supporting the approval of Telaprevir and Boceprevir, and information on polymerase inhibitors and IFN free proof of concept trials. Finally we discuss which patients should wait for DAA based therapies and which should be considered for peg IFN/RBV now.In the next 5 years our patients can expect higher response rates and truncated duration of therapy. They can expect drug cocktails or combos but for the next years these novel drugs will still require peg IFN and RBV. Also, a new era of resistance as a barrier to therapy will require sub typing and more viral monitoring. Overall, improved outcomes will come at the expense of more adverse events and increased costs of treatment.http://www.sciencedirect.com/science/article/pii/S1665268119317375Directly acting antivirals (DAA)Chronic hepatitis C (CHC)TelaprevirBoceprevir |
| spellingShingle | Maribel Rodríguez-Torres On the cusp of change: New therapeutic modalities for HCV Annals of Hepatology Directly acting antivirals (DAA) Chronic hepatitis C (CHC) Telaprevir Boceprevir |
| title | On the cusp of change: New therapeutic modalities for HCV |
| title_full | On the cusp of change: New therapeutic modalities for HCV |
| title_fullStr | On the cusp of change: New therapeutic modalities for HCV |
| title_full_unstemmed | On the cusp of change: New therapeutic modalities for HCV |
| title_short | On the cusp of change: New therapeutic modalities for HCV |
| title_sort | on the cusp of change new therapeutic modalities for hcv |
| topic | Directly acting antivirals (DAA) Chronic hepatitis C (CHC) Telaprevir Boceprevir |
| url | http://www.sciencedirect.com/science/article/pii/S1665268119317375 |
| work_keys_str_mv | AT maribelrodrigueztorres onthecuspofchangenewtherapeuticmodalitiesforhcv |